We are thrilled to announce that Pharmaseed was at the core basis of a treatment used during a successful phase IIb trial for Parkinson’s Disease led by Pharma Two B.
This success confirm and reinforce our track record in translational research. Based on an invention by I. Lamensdorf and Y. Sela, a suitable pharmaceutical carrier and a fixed dose combination of two active agents were developed in our company.
The combination of the two agents was challenged on our Parkinson’s Disease animal pre-clinical model, within Pharmaseed facilities. Beyond pre-clinical testing, translational research implies that our experts balanced-out regulatory, intellectual property along with clinical needs.
We warmly congratulate Pharma Two B, and we hope that this new treatment will help Parkinson’s Disease patients.